Advanced Accelerator Applications SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile
October 2018
62
About the Report
About the Report
Summary
Advanced Accelerator Applications SA (AAA), a Novartis company, is engaged in developing, producing and commercializing diagnostic and therapeutic molecular nuclear medicine products. The company's lead product candidate comprises Lutathera, NETSPOT, SOMAKIT TOC, Gluscan, Gluscan 500, Barnascan, Fluorochol, AAACholine, Cholscan, MIBITEC, Adamibi, Leukokit, Neurolite and Lumark. AAA develops new medicines which targets the orphan diseases in the field of cardiology, oncology, neurology and inflammation. It is also engaged in manufacturing Positron Emission tomography (PET) and single-photon emission computed tomography (SPECT). The company operates in France, Italy, the UK, Germany, Switzerland, Spain, Poland, Portugal, Israel, the US, and Canada, among others. AAA is headquartered in Saint-Genis-Pouilly, Auvergne, France.
Advanced Accelerator Applications SA-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Advanced Accelerator Applications SA, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Advanced Accelerator Applications SA, Medical Devices Deals, 2012 to YTD 2018 10
Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Advanced Accelerator Applications Raises USD26 Million in Venture Financing 13
Advanced Accelerator Applications Raises USD 56 Million In Venture Financing 14
Advanced Accelerator Raises USD 6 Million In First Tranche Of Venture Financing 15
Partnerships 16
Advanced Accelerator Applications Enters into Agreement with National Cancer Institute 16
Vect-Horus Enters into Collaboration Agreement with Advanced Accelerator Applications for Radio-Imaging Agents 17
Licensing Agreements 18
Advanced Accelerator Enters into Licensing Agreement with Cancer Targeted Technology 18
Advanced Accelerator Applications Enters into Licensing Agreement with Erasmus University Medical Center and Demokritos National Center 19
Advanced Accelerator Applications Enters into Licensing Agreement with Johns Hopkins University 20
Fujifilm RI Pharma Enters into Licensing Agreement with Advanced Accelerator Applications 21
Equity Offering 22
Advanced Accelerator Applications Prices Public Offering of American Depositary Shares for USD172.5 Million 22
Advanced Accelerator Applications to Raise up to USD80 Million in IPO 24
Acquisition 26
Novartis Acquires Advanced Accelerator Applications for USD3.9 Billion 26
Advanced Accelerator Applications Acquires IDB Group 28
Advanced Accelerator Applications Acquires Remaining 49.9% Stake in Atreus Pharma 29
Advanced Accelerator Applications SA-Key Competitors 30
Advanced Accelerator Applications SA-Key Employees 31
Advanced Accelerator Applications SA-Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Recent Developments 34
Financial Announcements 34
Nov 17, 2017: Advanced Accelerator Applications Reports 39% Sales Growth for Third Quarter 2017 34
Aug 31, 2017: Advanced Accelerator Applications Reports 32% Sales Growth for Second Quarter 2017 35
May 31, 2017: Advanced Accelerator Applications Reports 21% Sales Growth for First Quarter 2017 37
Mar 23, 2017: Advanced Accelerator Applications Reports 23% Sales Growth for Fiscal 2016; Continued NETSPOT Launch Success 39
Corporate Communications 41
May 25, 2017: Advanced Accelerator Applications Appoints Christine Mikail to Board of Directors 41
Product News 42
09/29/2017: Advanced Accelerator Applications Announces European Approval of Lutetium (177Lu) Oxodotreotide (Lutathera) for Gastroenteropancreatic Neuroendocrine (GEP-NET) Tumors 42
07/28/2017: EMA Recommends Granting a Marketing Authorisation for Lutetium (177Lu) Oxodotreotide 43
07/21/2017: Advanced Accelerator Applications Announces Positive CHMP Opinion Recommending Approval of Lutetium 177Lu Oxodotreotide (Lutathera) for Gastroenteropancreatic Neuroendocrine (GEP-NET) Tumors 44
03/21/2018: Lenox Hill successfully treats esthesioneuroblastoma with PRRT 45
01/26/2018: Lutathera Drug Approved for Pancreatic Neuroendocrine Tumors 46
01/26/2018: Advanced Accelerator Applications Receives FDA Approval for Lutathera for Treatment of Gastroenteropancreatic Neuroendocrine Tumors 47
Product Approvals 48
Aug 28, 2017: Advanced Accelerator Applications Announces New Prescription Drug User Fee Act date of January 26, 2018, for Lutetium Lu 177 Dotatate (Lutathera) 48
Jul 27, 2017: Advanced Accelerator Applications Completes Resubmission of NDA for Lutetium Lu 177 Dotatate (Lutathera) to FDA 49
Jan 09, 2017: Advanced Accelerator Applications CEO Provides Progress Report on Corporate Developments of 2016; Asserts Confidence in Ability to Address FDA Comments on Lutathera NDA 50
Clinical Trials 52
Jun 12, 2018: Newly-Approved Therapy Provides Improved Quality of Life for Patients with Advanced Metastatic Midgut Neuroendocrine Tumors 52
Jun 07, 2018: Novartis announces JCO publication of Lutathera NETTER-1 data showing significantly longer time to deterioration of key quality of life measures in patients with progressive midgut NETs 53
Feb 21, 2018: New Cancer Treatment for Neuroendocrine Tumors 54
Sep 06, 2017: Advanced Accelerator Applications Announce First Patient in Bridging Study in Japan for Lutetium Lu 177 Dotatate (Lutathera) 55
Jun 12, 2017: Targeted Radionuclide Treatment for Neuroendocrine Tumors Improves Quality of Life 56
Mar 06, 2017: Advanced Accelerator Applications Announces Presentation of Quality of Life Findings from NETTER-1 Phase III Study at ENETS 57
Jan 12, 2017: Advanced Accelerator Applications Announces New England Journal of Medicine Publication of Lutathera NETTER-1 Phase III Results 58
Jan 12, 2017: New drug in development shows improved survival for patients with advanced metastat 59
Other Significant Developments 60
Jan 09, 2017: Advanced Accelerator Applications CEO Provides Progress Report on Corporate Developments of 2016; Asserts Confidence in Ability to Address FDA Comments on Lutathera NDA 60
Appendix 62
Methodology 62
About GlobalData 62
Contact Us 62
Disclaimer 62
List of Figure
List of Figures
Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Advanced Accelerator Applications SA, Medical Devices Deals, 2012 to YTD 2018 10
List of Table
List of Tables
Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Key Facts 2
Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Advanced Accelerator Applications SA, Deals By Therapy Area, 2012 to YTD 2018 9
Advanced Accelerator Applications SA, Medical Devices Deals, 2012 to YTD 2018 10
Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Advanced Accelerator Applications Raises USD26 Million in Venture Financing 13
Advanced Accelerator Applications Raises USD 56 Million In Venture Financing 14
Advanced Accelerator Raises USD 6 Million In First Tranche Of Venture Financing 15
Advanced Accelerator Applications Enters into Agreement with National Cancer Institute 16
Vect-Horus Enters into Collaboration Agreement with Advanced Accelerator Applications for Radio-Imaging Agents 17
Advanced Accelerator Enters into Licensing Agreement with Cancer Targeted Technology 18
Advanced Accelerator Applications Enters into Licensing Agreement with Erasmus University Medical Center and Demokritos National Center 19
Advanced Accelerator Applications Enters into Licensing Agreement with Johns Hopkins University 20
Fujifilm RI Pharma Enters into Licensing Agreement with Advanced Accelerator Applications 21
Advanced Accelerator Applications Prices Public Offering of American Depositary Shares for USD172.5 Million 22
Advanced Accelerator Applications to Raise up to USD80 Million in IPO 24
Novartis Acquires Advanced Accelerator Applications for USD3.9 Billion 26
Advanced Accelerator Applications Acquires IDB Group 28
Advanced Accelerator Applications Acquires Remaining 49.9% Stake in Atreus Pharma 29
Advanced Accelerator Applications SA, Key Competitors 30
Advanced Accelerator Applications SA, Key Employees 31
Advanced Accelerator Applications SA, Subsidiaries 32
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.